Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

Armando Sardi; Carlos A Muñoz-Zuluaga; Michelle Sittig; Teresa Diaz-Montes

doi:10.1002/ccr3.1491

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

Clin Case Rep. 2018 May 2;6(6):1142-1152. doi: 10.1002/ccr3.1491. eCollection 2018 Jun.

Authors

Armando Sardi¹, Carlos A Muñoz-Zuluaga¹, Michelle Sittig¹, Teresa Diaz-Montes¹

Affiliation

¹ The Institute for Cancer Care Mercy Medical Center 227 St. Paul Place Baltimore 21202-2001 Maryland.

Abstract

Peritoneal sarcomatosis from uterine sarcoma is a rare disease with no effective treatment and poor prognosis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has successful results in peritoneal carcinomatosis from gastrointestinal/gynecological origins. We show that CRS/HIPEC is safe, feasible, and may benefit selected patients with peritoneal sarcomatosis from uterine sarcoma.

Keywords: Cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal sarcomatosis; uterine sarcoma.

Publication types

Case Reports